A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (Aged 2 to 11 Years) With Moderate-to-Severe Atopic Dermatitis

Nemolizumab

Nemolizumab

Nemolizumab

Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Nemolizumab

Time to Reach the Maximum Observed Serum Concentration (Tmax) of Nemolizumab

Maximum Observed Serum Concentration (Cmax) of Nemolizumab

Nemolizumab Serum Concentrations of Pediatric Participants

Apparent Total Body Clearance (Cl/F) of Nemolizumab

Apparent Volume of Distribution (Vd/F) of Nemolizumab

Absorption Rate Constant (Ka) of Nemolizumab

Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Nemolizumab

Apparent Terminal Half-life (t1/2) of Nemolizumab

Number of Participants with Treatment Emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESIs), Adverse Events Leading to Discontinuation and Serious Adverse Events (SAEs)

Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Each Visit up to Week 52

Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score at Each Visit up to Week 52

Number of Participants Achieving 50%, 75% or 90% Response From Baseline in Eczema Area and Severity Index (EASI-50, EASI-75 and EASI-90) at Each Visit up to Week 52

Investigator's Global Assessment (IGA) Success Rate at Each Visit up to Week 52

Change From Baseline in Body Surface Area (BSA) Involvement by Atopic Dermatitis (AD)

Absolute Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (PP NRS) Score at Each Visit up to Week 52

Percent Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (PP NRS) Score at Each Visit up to Week 52

Proportion of Participants With an Improvement of >= 4 From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (PP NRS) at Each Visit up to Week 52

Absolute Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Each Visit up to Week 52

Percent Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Each Visit up to Week 52

Absolute Change From Baseline in Weekly Average of Sleep Disturbance Numeric Rating Scale (NRS) Score at Each Visit up to Week 52

Percent Change From Baseline in Weekly Average of Sleep Disturbance Numeric Rating Scale (NRS) Score at Each Visit up to Week 52

Proportion of Participants Receiving any Rescue Therapy by Rescue Treatment

Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Each Visit up to Week 52

Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) For Participants >=4 Years of Age up to Week 16 and Week 52

Change From Baseline in Infants' Dermatology Life Quality Index (iDLQI) For Participants <4 Years of Age From Baseline up to Week 16 and up to Week 52

Change From Baseline in Patient-Oriented Eczema Measure (POEM) up to Week 16 and Week 52

Pharmacokinetic (PK)/Pharmacodynamic (PD) Relationship Between Nemolizumab Serum Concentration and Changes in Peak Pruritus Numeric Rating Scale (PP NRS)

Pharmacokinetic (PK)/Pharmacodynamic (PD) Relationship Between Nemolizumab Serum Concentration and Changes in Eczema Area and Severity Index (EASI) Score

Pharmacokinetic (PK)/Pharmacodynamic (PD) Relationship Between Nemolizumab Serum Concentration and Changes in Investigator's Global Assessment (IGA) Score

Number of Participants with Positive Anti-Drug Antibody (ADA) for Nemolizumab